Emerging Therapies for Myasthenia Gravis
Pritikanta Paul, MD, is an Assistant Professor in the Department of Neurology and Rehabilitation at University of Illinois at Chicago, and a neurologist with UI Health. Here Dr. Paul reviews new therapies that have been and are being developed to treat the autoimmune disease myasthenia gravis. He explains terms like “complement inhibitor” and “Fc receptor inhibitor” and addresses treatment options such as Ultomiris, Soliris, Vyvgart, as well as emerging therapies that target B cells, T cells, and other disease pathways.
▶︎
Advances in the Treatment of Myasthenia Gravis
▶︎
Interview With MG Patient J'Sean Nunnery // Part 1 of 3
▶︎
Integrating FcRn and Complement System Therapies for Generalized Myasthenia Gravis
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
Clinical Trials and Emerging Therapies in Myasthenia Gravis - B. Jane Distad, MD
▶︎
Myasthenia gravis is a big deal to anesthesiologists
▶︎
Living with Myasthenia Gravis
▶︎
How to Use Methylation Supplements Safely If You Have MTHFR
▶︎
Vyvgart For Myasthenia Gravis: A Pharmacist's Thoughts
▶︎
MG & Exercise - Demonstration
▶︎
An Overview of Living Kidney Donation at Northwestern Memorial Hospital
▶︎
Assessment of GCA and PMR
▶︎
The Gold Standard for Treatment — Unshame North Carolina Webinar
▶︎
2022 MGFA National Patient Conference: Seronegative: How to Navigate this Diagnosis
▶︎
Polycystic Liver Disease (PLD), Q&A - PLD a condition with many more questions than answers
▶︎
Seronegative MG with Dr. Allan Weiss and the MGA
▶︎
Interview With MG Patient Kathryn Wotman // Part 1 of 3
▶︎
George Bakris, MD | Use of Finerenone in Patients with Diabetes Who Have Kidney Disease
▶︎
Restoring More Than Hair: Addressing the Whole Patient with Alopecia Areata (AA) Webinar
▶︎